Changes of Cine Cerebrospinal Fluid Dynamics in Patients with MS
[URL="http://www.ncbi.nlm.nih.gov/pubmed/23523158"]Changes of Cine Cerebrospinal Fluid Dynamics[/URL] in Patients with Multiple Sclerosis Treated with Percutaneous Transluminal Angioplasty: A Case-control Study - oa Zamboni en Zivadinov
[QUOTE][B]PURPOSE[/B]:
To investigate characteristics of cine phase contrast-calculated cerebrospinal fluid (CSF) flow and velocity measures in patients with relapsing-remitting (RR) multiple sclerosis (MS) receiving standard medical treatment who had been diagnosed with chronic cerebrospinal venous insufficiency (CCSVI) and underwent percutaneous transluminal angioplasty (PTA).
[B]MATERIALS AND METHODS[/B]:
This case-controlled, magnetic resonance (MR) imaging-blinded study included 15 patients with RR MS who presented with significant stenoses (≥50% lumen reduction on catheter venography) in the azygous or internal jugular veins. Eight patients underwent PTA in addition to medical therapy immediately following baseline assessments (case group) and seven had delayed PTA after 6 months of medical therapy alone (control group). CSF flow and velocity measures were quantified over 32 phases of the cardiac cycle by a semiautomated method. Outcomes were compared between groups at baseline and at 6 and 12 months of the study by mixed-effect model analysis.
[B]RESULTS[/B]:
At baseline, no significant differences in CSF flow or velocity measures were detected between groups. At month 6, significant improvement in flow (P<.001) and velocity (P = .013) outcomes were detected in the immediate versus the delayed group, and persisted to month 12 (P = .001 and P = .021, respectively). Within-group flow comparisons from baseline to follow-up showed a significant increase in the immediate group (P = .033) but a decrease in the delayed group (P = .024). Altered CSF flow and velocity measures were associated with worsening of clinical and MR outcomes in the delayed group.
[B]CONCLUSIONS[/B]:
PTA in patients with MS with CCSVI increased CSF flow and decreased CSF velocity, which are indicative of improved venous parenchyma drainage.[/QUOTE]
CCSVI - 9
-
Jolande
-
Robbie
Morphological and haemodynamic abnormalities in the jugular veins of patients with mu
Morphological and haemodynamic abnormalities in the jugular veins of patients with mu
[url]http://phl.sagepub.com/content/27/4/168.abstract[/url]
[QUOTE]Objectives
Multiple areas of stenosis and different levels of obstruction of internal jugular and azygous veins (a condition known as cronic cerebrospinal venous insufficiency) recently emerged as an additional theory to the well-known autoimmune concept, explaining etiology of multiple sclerosis (MS). The aim of our study was to evaluate internal jugular vein (IJV) morphology and haemodynamic characteristics in patients with MS and compare it with well-matched healthy individuals and to evaluate the prevalence of venous flow abnormalities in both groups.
Methods
Sixty-four patients with clinically proven MS and 37 healthy individuals were included in our study. In all patients, IJV morphology and haemodynamic characteristics were evaluated by colour Doppler sonography as well as venous flow disorder. The patients were classified into four groups according to MS clinical form presentation. The prevalence of morphological and haemodynamic abnormalities in the IJV were assessed.
Results
The presence of stenosing lesion, mostly intraluminal defects like abnormal IJV valves, were observed in 28 patients (43%) in the MS group, and in 17 patients (45.9%) in the control group (P = NS). By adding haemodynamic Doppler information in the IJV venous outflow was significantly different in 42% of MS patients showing flow abnormalities (27/64), as compared with 8.1% of the controls (3/37), P < 0.001.
Conclusion
In our group of patients, patients suffering from MS had significantly more IJV morphological changes and haemodynamic abnormalities when compared with healthy individuals not suffering from MS. These findings can be well demonstrated by non-invasive and cost-effective Doppler ultrasound.[/QUOTE]
Kweet niet of we deze al hebben...
[url]http://phl.sagepub.com/content/27/4/168.abstract[/url]
[QUOTE]Objectives
Multiple areas of stenosis and different levels of obstruction of internal jugular and azygous veins (a condition known as cronic cerebrospinal venous insufficiency) recently emerged as an additional theory to the well-known autoimmune concept, explaining etiology of multiple sclerosis (MS). The aim of our study was to evaluate internal jugular vein (IJV) morphology and haemodynamic characteristics in patients with MS and compare it with well-matched healthy individuals and to evaluate the prevalence of venous flow abnormalities in both groups.
Methods
Sixty-four patients with clinically proven MS and 37 healthy individuals were included in our study. In all patients, IJV morphology and haemodynamic characteristics were evaluated by colour Doppler sonography as well as venous flow disorder. The patients were classified into four groups according to MS clinical form presentation. The prevalence of morphological and haemodynamic abnormalities in the IJV were assessed.
Results
The presence of stenosing lesion, mostly intraluminal defects like abnormal IJV valves, were observed in 28 patients (43%) in the MS group, and in 17 patients (45.9%) in the control group (P = NS). By adding haemodynamic Doppler information in the IJV venous outflow was significantly different in 42% of MS patients showing flow abnormalities (27/64), as compared with 8.1% of the controls (3/37), P < 0.001.
Conclusion
In our group of patients, patients suffering from MS had significantly more IJV morphological changes and haemodynamic abnormalities when compared with healthy individuals not suffering from MS. These findings can be well demonstrated by non-invasive and cost-effective Doppler ultrasound.[/QUOTE]
Kweet niet of we deze al hebben...
-
Marsei
[QUOTE=Robbie;918703]
Kweet niet of we deze al hebben...[/QUOTE]
In [URL="http://www.msweb.nl/forum/showpost.php? ... tcount=315"]2011[/URL] ;)
Kweet niet of we deze al hebben...[/QUOTE]
In [URL="http://www.msweb.nl/forum/showpost.php? ... tcount=315"]2011[/URL] ;)
-
Marsei
CCSVI Weekly News Digest
CCSVI Weekly News Digest
[URL="http://paper.li/CCSVI_Society/130648418 ... =paper_sub"][U]CCSVI Weekly News Digest[/U][/URL]
[URL="http://paper.li/CCSVI_Society/130648418 ... =paper_sub"][U]CCSVI Weekly News Digest[/U][/URL]
-
Robbie
[QUOTE=Marsei;918725]In [URL="http://www.msweb.nl/forum/showpost.php? ... tcount=315"]2011[/URL] ;)[/QUOTE]
Yep, komt dan weer ergens naar boven:D
Maar Ja, de pta en csf zie je ook her en der...is ook hetzelfde onderzoek...beetje komkommertijd :haha:
[url]http://registration.akm.ch/einsicht.php ... KEN_ID=900[/url]
Ach ja, tis ook best veel.....
Yep, komt dan weer ergens naar boven:D
Maar Ja, de pta en csf zie je ook her en der...is ook hetzelfde onderzoek...beetje komkommertijd :haha:
[url]http://registration.akm.ch/einsicht.php ... KEN_ID=900[/url]
Ach ja, tis ook best veel.....
-
Marsei
Hubbard Foundation Newsletter
Hubbard Foundation Newsletter
Hubbard Foundation Newsletter - June Edition
[QUOTE]FDA update: On June 10,2013 the FDA responded to our latest revision of our application for the Multi-Center-Registry of CCSVI treatment and follow-up. Our initial application was submitted in November 2012.
Because of the Buffalo pilot study news release suggesting that venoplasty might actually worsen MS (although the data itself showed no statistically significant changes) the FDA is now requiring evaluations by neurologists, including an EDSS score before and 1 year after venoplasty treatment in the study.
We have decided not to dispute this request because most patients should be able to obtain these evaluations covered by their health insurance. The FDA has also requested that the IR perform ultrasounds to look for blood clots after the venoplasty. We hope this is the last FDA request for revisions. [/QUOTE]
Hubbard Foundation Newsletter - June Edition
[QUOTE]FDA update: On June 10,2013 the FDA responded to our latest revision of our application for the Multi-Center-Registry of CCSVI treatment and follow-up. Our initial application was submitted in November 2012.
Because of the Buffalo pilot study news release suggesting that venoplasty might actually worsen MS (although the data itself showed no statistically significant changes) the FDA is now requiring evaluations by neurologists, including an EDSS score before and 1 year after venoplasty treatment in the study.
We have decided not to dispute this request because most patients should be able to obtain these evaluations covered by their health insurance. The FDA has also requested that the IR perform ultrasounds to look for blood clots after the venoplasty. We hope this is the last FDA request for revisions. [/QUOTE]
-
Marsei
Brain’s ‘Garbage Truck’ May Hold Key to Treating Alzheimer’s and Other Disorders
Brain’s ‘Garbage Truck’ May Hold Key to Treating Alzheimer’s and Other Disorders
[URL="http://www.urmc.rochester.edu/news/stor ... fm?id=3870"][U]Brain’s ‘Garbage Truck’[/U][/URL] May Hold Key to Treating Alzheimer’s and Other Disorders
[QUOTE]In a perspective piece appearing today in the journal Science, researchers at University of Rochester Medical Center (URMC) point to a newly discovered system by which the brain removes waste as a potentially powerful new tool to treat neurological disorders like Alzheimer’s disease. In fact, scientists believe that some of these conditions may arise when the system is not doing its job properly.
[/QUOTE]
[QUOTE]“The idea that ‘dirty brain’ diseases like Alzheimer may result from a slowing down of the glymphatic system as we age is a completely new way to think about neurological disorders,” said Nedergaard. “It also presents us with a new set of targets to potentially increase the efficiency of glymphatic clearance and, ultimately, change the course of these conditions.”[/QUOTE]
[URL="http://www.urmc.rochester.edu/news/stor ... fm?id=3870"][U]Brain’s ‘Garbage Truck’[/U][/URL] May Hold Key to Treating Alzheimer’s and Other Disorders
[QUOTE]In a perspective piece appearing today in the journal Science, researchers at University of Rochester Medical Center (URMC) point to a newly discovered system by which the brain removes waste as a potentially powerful new tool to treat neurological disorders like Alzheimer’s disease. In fact, scientists believe that some of these conditions may arise when the system is not doing its job properly.
[/QUOTE]
[QUOTE]“The idea that ‘dirty brain’ diseases like Alzheimer may result from a slowing down of the glymphatic system as we age is a completely new way to think about neurological disorders,” said Nedergaard. “It also presents us with a new set of targets to potentially increase the efficiency of glymphatic clearance and, ultimately, change the course of these conditions.”[/QUOTE]
-
zeiler
Jolande, ik was gister ergens en Marc was daar ook, ik vroeg hem hoe het tegenwoordig (had hem een paar maanden niet gezien of gesproken) met zijn bloeddruk was (had je om gevraagd). Dat was nog steeds 'perfect' en hij gebruikte nog steeds helemaal geen medicijnen daarvoor. Heb hem trouwens verteld over mijn laatste bevindingen over Robbie en Van Noort. Ook hij vond dat enorm verassend en vroeg aan mij wat de doorslag had gegeven voor mijn gewijzigde indruk. Dat is grappig, zei ik, meneer Aars vroeg dat ook al, maar daarna hoorde ik niets meer van. Hij zei dat hem dat niet echt verbaasde; 'die relnicht wil alleen maar narigheid horen, want zo is ie zelf'. Grappig hè.